MP28-08 SMOKING AND INCIDENCE AND PROGRESSION OF LOWER URINARY TRACT SYMPTOMS (LUTS) IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology & Evaluation (MP28)1 Sep 2021MP28-08 SMOKING AND INCIDENCE AND PROGRESSION OF LOWER URINARY TRACT SYMPTOMS (LUTS) IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL Jordan J. Kramer, Illona Csizmadi, Lin Gu, Daniel Moreira, Gerald Andriole, and Stephen J. Freedland Jordan J. KramerJordan J. Kramer More articles by this author , Illona CsizmadiIllona Csizmadi More articles by this author , Lin GuLin Gu More articles by this author , Daniel MoreiraDaniel Moreira More articles by this author , Gerald AndrioleGerald Andriole More articles by this author , and Stephen J. FreedlandStephen J. Freedland More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002025.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Benign prostatic hyperplasia (BPH) is common in older men, with many developing lower urinary tract symptoms (LUTS) that impair quality of life. Smoking has many well-established adverse effects, but its effects on BPH and associated LUTS are unclear. We sought to determine if smoking is a risk factor for the incidence of LUTS in asymptomatic men and for the progression of LUTS in symptomatic men. METHODS: A post-hoc analysis of REDUCE was carried out in 3060 asymptomatic/minimally symptomatic (aka “asymptomatic”) men with baseline International Prostate Symptom Score (IPSS) <8 and in 2198 symptomatic men with baseline IPSS ≥8 not taking α-blockers or 5α-reductase inhibitor medications. We estimated multivariable adjusted hazard ratios (adj-HRs) and 95% confidence intervals (CIs) using Cox proportional hazard models to assess the association between smoking at baseline and LUTS incidence and progression. Among asymptomatic men, incident LUTS was defined as the first report of medical treatment, surgery or sustained clinically significant LUTS (i.e. 2 reports of IPSS>14). Among symptomatic men, LUTS progression was defined as an IPSS increase of ≥4 points from baseline, any surgical procedure for BPH, or the start of a new BPH drug. RESULTS: Of 3060 asymptomatic men, 15% (n=467) were current, 40% (n=1231) former and 45% (n=1362) never-smokers. Of 2198 symptomatic men, 14% (n=320) were current, 39% (n=850) former and 47% (n=1028) never-smokers. In asymptomatic men, compared with never-smokers, current and former smoking at baseline was not associated with LUTS incidence (adj-HR=1.08; 95% CI: 0.78-1.48 and adj-HR=1.01; 95% CI: 0.80-1.30, for current and former smoking status, respectively). In symptomatic men, compared with never-smokers, current and former smoking at baseline was not associated with the progression of LUTS (adj-HR=1.11; 95% CI: 0.92-1.33 and adj-HR=1.03; 95% CI: 0.90-1.18, for current and former smoking status, respectively). Similar results were seen in dutasteride and placebo arms in data stratified by treatment assignment. CONCLUSIONS: In the REDUCE study, smoking status was not associated with either incident LUTS in asymptomatic men or progression of LUTS in symptomatic men. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e483-e484 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jordan J. Kramer More articles by this author Illona Csizmadi More articles by this author Lin Gu More articles by this author Daniel Moreira More articles by this author Gerald Andriole More articles by this author Stephen J. Freedland More articles by this author Expand All Advertisement Loading ...